

Göttingen, Germany | March 26, 2026

Sartorius AG Supervisory Board extends appointment of board member René Fáber

At today's meeting, the Supervisory Board of Sartorius AG resolved to extend the appointment of Dr. René Fáber as a member of the Executive Board by a five-year period to December 31, 2031. René Fáber (50), who holds a Ph.D. in polymer chemistry from the Technical University of Munich, joined Sartorius as a scientist in 2002. He held several management positions before being appointed to the Executive Board in January 2019. In this role, he is responsible for the Bioprocess Solutions Division.

Further Information

[CV of René Fáber](#)

Financial calendar

April 23, 2026	Publication of first quarter results January to March 2026
July 23, 2026	Publication of half-year results for January to June 2026
October 22, 2026	Publication of nine-month results January to September 2026

A profile of Sartorius

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Göttingen-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees serve customers around the globe.

Visit our [newsroom](#) or follow Sartorius on [LinkedIn](#).

Contact

Verena Sattel
External Communications
+49 551 308 4067
verena.sattel@sartorius.com